A Phase 1, Randomised, Double Blind, Placebo Controlled, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of ASLAN003 in Healthy Subjects
Latest Information Update: 18 Apr 2023
At a glance
- Drugs Farudodstat (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors ASLAN Pharmaceuticals
- 02 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Nov 2013 New trial record